Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) have vast therapeutic potential for the treatment for neurological diseases and damage, with many of their effects mediated by components of the stem cell secretome.

Mesenchymal stem cells (MSCs) have direct effects on islet β‐cells that improve their insulin secretory function, and studies have highlighted the essential nature of the generation of ATP and other metabolic coupling factors by mitochondrial metabolism for nutrient‐induced insulin secretion.

While various stem cell-based therapeutics are currently under investigation as a treatment option following trauma, such as brain or lung injury, stem cells readily express tissue factor (TF), which causes rapid blood clotting.

While mesenchymal stem cells (MSCs) have been reported to prevent renal injuries via immune regulation in diabetic models, the mechanisms at play remain to be fully elucidated.

A recent STEM CELLS Translational Medicine

A case report published in STEM CELLS Translational Medicine 

A new STEM CELLS article from the lab of Ivo Kalajzic (UConn Health, Farmington, Connecticut, USA) recently presented a novel translational approach for the treatment of osteogenesis imperfecta (OI).

Researchers define an optimal population of rat meniscus tendon tissue-derived mesenchymal stem cells for use in meniscus repair and osteoarthritis suppression

Despite the promise of stem cell‐based therapies as a treatment option for osteoarthritis (OA), results have fallen short of expectations.

A new study from the lab of Martin Grumet (Rutgers University, Piscataway, NJ, USA) assessed clinical